Background: The benefits of pharmaceutical innovations are widely diffused; they accrue to the healthcare providers, patients, employers, and manufacturers. We estimate the societal monetary benefits of simvastatin in Canada and its distribution among different beneficiaries overtime.
- Chronic Diseases / Disorders
- Fetal Alcohol Spectrum Disorder (FASD)
- Health Economics / Healthcare Costs
- Health Measurement Tools
- Health Policy
- Healthcare Services
- Infectious Diseases
- Maternal and Child Health
- Mental Health
- Quality of Life
The outcome of IHE initiatives is providing better information for developing health policy and best medical practices. IHE disseminates information in many ways. In addition to publications in peer-reviewed journals, IHE produces books and a variety of reports synthesizing information in a particular field.
If you cannot find the publication or report you are seeking, please contact us at [email protected]. Thank you!
Refine your search by clicking filters to the left.
OBJECTIVES: In Canada, most mental health services are embedded in the publichealth care system. Little is known of the cost distribution within the mental healthpopulation. Our study aims to estimate the depression care costs of patients with adepression diagnosis, ranking them by the increasing total depression health carecosts.
PURPOSE: This longitudinal study assessed the changes in drug use patterns and health-related quality of life (HRQL) among HIV-positive drug users in the first methadonemaintenance treatment (MMT) cohort in Vietnam.
This study measures the return on investment for parent training at the pre- or early childhood stage. The purpose is to prevent conduct disorders in childhood, and mental health problems in adolescence and adulthood. The program studied is the Triple P program. The context is a one year birth cohort in Alberta. The costs are for a universal parental training program. The downstream…